$233.47
+11.66
(+5.26%)▲
3.94%
Downside
Day's Volatility :4.03%
Upside
0.09%
30.76%
Downside
52 Weeks Volatility :41.22%
Upside
15.1%
Period | Charles River Laboratories International | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -3.15% | 6.5% | 5.9% |
6 Months | 0.69% | 7.1% | 10.4% |
1 Year | 4.12% | 9.8% | 18.2% |
3 Years | -43.6% | 14.2% | 22.1% |
Market Capitalization | 11.5B |
Book Value | $70.67 |
Earnings Per Share (EPS) | 8.52 |
PE Ratio | 26.1 |
PEG Ratio | 1.87 |
Wall Street Target Price | 254.8 |
Profit Margin | 10.81% |
Operating Margin TTM | 14.15% |
Return On Assets TTM | 4.95% |
Return On Equity TTM | 13.14% |
Revenue TTM | 4.1B |
Revenue Per Share TTM | 80.13 |
Quarterly Revenue Growth YOY | -1.7000000000000002% |
Gross Profit TTM | 1.5B |
EBITDA | 949.6M |
Diluted Eps TTM | 8.52 |
Quarterly Earnings Growth YOY | -0.35 |
EPS Estimate Current Year | 11.0 |
EPS Estimate Next Year | 12.34 |
EPS Estimate Current Quarter | 2.07 |
EPS Estimate Next Quarter | 2.65 |
What analysts predicted
Upside of 9.14%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 2.3B | ↑ 21.99% |
Net Income | 226.4M | ↑ 83.51% |
Net Profit Margin | 9.99% | ↑ 3.35% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.6B | ↑ 15.67% |
Net Income | 252.0M | ↑ 11.33% |
Net Profit Margin | 9.61% | ↓ 0.38% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 2.9B | ↑ 11.55% |
Net Income | 364.3M | ↑ 44.55% |
Net Profit Margin | 12.46% | ↑ 2.85% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 3.5B | ↑ 21.08% |
Net Income | 391.0M | ↑ 7.32% |
Net Profit Margin | 11.04% | ↓ 1.42% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 4.0B | ↑ 12.31% |
Net Income | 486.2M | ↑ 24.36% |
Net Profit Margin | 12.23% | ↑ 1.19% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 4.1B | ↑ 3.86% |
Net Income | 474.6M | ↓ 2.39% |
Net Profit Margin | 11.49% | ↓ 0.74% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↑ 11.19% |
Net Income | 187.4M | ↑ 94.26% |
Net Profit Margin | 17.04% | ↑ 7.29% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↓ 6.41% |
Net Income | 103.1M | ↓ 44.97% |
Net Profit Margin | 10.02% | ↓ 7.02% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↑ 2.97% |
Net Income | 97.0M | ↓ 5.93% |
Net Profit Margin | 9.15% | ↓ 0.87% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↓ 3.14% |
Net Income | 87.4M | ↓ 9.93% |
Net Profit Margin | 8.51% | ↓ 0.64% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↓ 1.28% |
Net Income | 187.1M | ↑ 114.08% |
Net Profit Margin | 18.46% | ↑ 9.95% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↓ 0.19% |
Net Income | 67.3M | ↓ 64.01% |
Net Profit Margin | 6.66% | ↓ 11.8% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 3.9B | ↑ 31.6% |
Total Liabilities | 2.5B | ↑ 34.93% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 4.7B | ↑ 21.7% |
Total Liabilities | 3.0B | ↑ 20.21% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 5.5B | ↑ 17.01% |
Total Liabilities | 3.3B | ↑ 10.6% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 7.0B | ↑ 27.93% |
Total Liabilities | 4.4B | ↑ 32.42% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 7.6B | ↑ 8.24% |
Total Liabilities | 4.6B | ↑ 3.32% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 8.2B | ↑ 7.79% |
Total Liabilities | 4.5B | ↓ 0.94% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 7.6B | ↑ 2.98% |
Total Liabilities | 4.6B | ↓ 2.79% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.7B | ↑ 1.27% |
Total Liabilities | 4.5B | ↓ 0.8% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.8B | ↑ 0.95% |
Total Liabilities | 4.5B | ↓ 1.55% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.6B | ↓ 2.13% |
Total Liabilities | 4.3B | ↓ 4.83% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 8.2B | ↑ 7.73% |
Total Liabilities | 4.5B | ↑ 6.57% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 8.2B | ↓ 0.52% |
Total Liabilities | 4.4B | ↓ 1.92% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 441.1M | ↑ 39.48% |
Investing Cash Flow | -955.0M | ↑ 1215.68% |
Financing Cash Flow | 558.1M | ↓ 367.69% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 480.9M | ↑ 9.02% |
Investing Cash Flow | -681.5M | ↓ 28.64% |
Financing Cash Flow | 231.9M | ↓ 58.44% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 546.6M | ↑ 13.65% |
Investing Cash Flow | -601.5M | ↓ 11.73% |
Financing Cash Flow | 47.2M | ↓ 79.63% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 760.8M | ↑ 39.19% |
Investing Cash Flow | -1.4B | ↑ 139.04% |
Financing Cash Flow | 672.6M | ↑ 1323.55% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 619.6M | ↓ 18.55% |
Investing Cash Flow | -607.9M | ↓ 57.72% |
Financing Cash Flow | -42.4M | ↓ 106.3% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 234.8M | ↑ 76.8% |
Investing Cash Flow | 44.4M | ↓ 106.8% |
Financing Cash Flow | -249.0M | ↑ 382.53% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 109.4M | ↓ 53.41% |
Investing Cash Flow | -168.6M | ↓ 479.92% |
Financing Cash Flow | 25.2M | ↓ 110.14% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 148.1M | ↑ 35.42% |
Investing Cash Flow | -76.6M | ↓ 54.57% |
Financing Cash Flow | -71.5M | ↓ 383.13% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 205.5M | ↑ 38.7% |
Investing Cash Flow | -324.8M | ↑ 323.95% |
Financing Cash Flow | -162.9M | ↑ 127.9% |
Sell
Neutral
Buy
Charles River Laboratories International is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Charles River Laboratories International | 7.3% | 0.69% | 4.12% | -43.6% | 58.51% |
![]() Idexx Laboratories, Inc. | -3.67% | -10.34% | -15.37% | -31.35% | 65.77% |
![]() Agilent Technologies Inc. | 1.42% | 3.05% | 5.07% | -10.16% | 94.22% |
![]() Thermo Fisher Scientific, Inc. | 6.51% | 8.62% | 3.5% | 12.36% | 106.99% |
![]() Danaher Corp. | 6.51% | 15.92% | 1.97% | -6.92% | 89.83% |
![]() Iqvia Holdings Inc. | 10.0% | 7.5% | 0.14% | -6.07% | 45.29% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Charles River Laboratories International | 26.1 | 26.1 | 1.87 | 11.0 | 0.13 | 0.05 | NA | 70.67 |
![]() Idexx Laboratories, Inc. | 45.67 | 45.67 | 4.75 | 11.06 | 0.72 | 0.23 | NA | 18.93 |
![]() Agilent Technologies Inc. | 31.63 | 31.63 | 2.7 | 5.2 | 0.21 | 0.08 | 0.01 | 21.31 |
![]() Thermo Fisher Scientific, Inc. | 35.72 | 35.72 | 2.81 | 21.71 | 0.14 | 0.05 | 0.0 | 120.87 |
![]() Danaher Corp. | 48.76 | 48.76 | 3.13 | 6.99 | 0.08 | 0.04 | 0.0 | 68.92 |
![]() Iqvia Holdings Inc. | 30.13 | 30.13 | 1.33 | 11.19 | 0.23 | 0.05 | NA | 36.83 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Charles River Laboratories International | Buy | $11.5B | 58.51% | 26.1 | 10.81% |
![]() Idexx Laboratories, Inc. | Buy | $38.8B | 65.77% | 45.67 | 23.26% |
![]() Agilent Technologies Inc. | Buy | $38.9B | 94.22% | 31.63 | 18.84% |
![]() Thermo Fisher Scientific, Inc. | Buy | $219.4B | 106.99% | 35.72 | 14.2% |
![]() Danaher Corp. | Buy | $191.9B | 89.83% | 48.76 | 17.83% |
![]() Iqvia Holdings Inc. | Buy | $42.3B | 45.29% | 30.13 | 9.39% |
Insights on Charles River Laboratories International
Revenue is down for the last 4 quarters, 1.05B → 1.01B (in $), with an average decrease of 1.5% per quarter
Netprofit is down for the last 2 quarters, 187.08M → 67.32M (in $), with an average decrease of 64.0% per quarter
In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 1.0%
In the last 3 years, Charles River Laboratories International has experienced a drawdown of -43.6%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 33.4%
Vanguard Group Inc
BlackRock Inc
State Street Corporation
Kayne Anderson Rudnick Investment Management LLC
ClearBridge Advisors, LLC
T. Rowe Price Associates, Inc.
charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro
Organization | Charles River Laboratories International |
Employees | 20400 |
CEO | Mr. James C. Foster J.D. |
Industry | Commercial Services |
Cubesmart
$233.47
+5.26%
Iqvia Holdings Inc.
$233.47
+5.26%
Microsectors Travel 3x Inlev
$233.47
+5.26%
Jack Henry & Associates Inc.
$233.47
+5.26%
Packaging Corporation Of America
$233.47
+5.26%
Cognizant Technology Solutions Corp.
$233.47
+5.26%
Synopsys Inc.
$233.47
+5.26%
Targa Resources Corp.
$233.47
+5.26%
Parker-hannifin Corporation
$233.47
+5.26%